Transcriptomics

Dataset Information

0

Transcriptome profiling of CXCR2+ neuroendocrine (NE) tumor cells purified from patients' fresh prostate adenocarcinoma


ABSTRACT: The development of therapy resistance is inevitable in prostate cancer (PCa) despite maximal inhibition of androgen receptor (AR) signaling. Here, we for the first time purified a rare AR-negative NE-cell subset from primary fresh human PCa tissue based on cell-surface receptor CXCR2 and showed that they possess gene signatures of lethal cancer through transcriptional profiling. Functional studies demonstrate CXCR2 to be a driver of NE cells’ key phenotypes, including loss of AR expression, lineage plasticity, and resistance to hormonal-therapy. Furthermore, CXCR2-driven NE cells are critical for the tumor microenvironment by providing a survival niche for the bulk AR+ luminal cells. Importantly, inhibition of CXCR2 by a chemical inhibitor or genetic manipulation dramatically inhibits aggressive PCa cells in-vitro and in-vivo, demonstrating a central role of NE cells in human PCa. Therefore, we firmly established that targeting NE cells through CXCR2 represents a novel, AR-independent therapeutic strategy that will eliminate all tumor cells (NE and luminal), achieving superior therapeutic efficacy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE114326 | GEO | 2019/12/03

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA470957 | ENA
2015-06-24 | E-GEOD-66187 | biostudies-arrayexpress
2019-08-21 | GSE125347 | GEO
2022-06-30 | GSE192373 | GEO
2020-10-07 | GSE140723 | GEO
2016-03-11 | E-GEOD-66851 | biostudies-arrayexpress
2024-10-03 | GSE245864 | GEO
2023-12-21 | GSE226555 | GEO
| PRJNA791301 | ENA
2023-12-21 | GSE226547 | GEO